ArticleAmerican journal of cancer research2026
GAS6 potentiates tumor progression through modulating suppressive microenvironments.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although growth arrest-specific 6 (GAS6), the principal ligand of the TAM receptors (TYRO3, AXL, and MERTK), acts as a central coordinator of efferocytosis, no pan-cancer analysis has been conducted. We thus first analyzed GAS6 across thirty-three tumors based on the datasets on TCGA (The Cancer Genome Atlas), TCGA-XENA (UCSC Xena), and other publicly available repositories. We observed a correlation of aberrant expression of GAS6 with malignant transformation and cancer progression, which strongly predicts worse overall survival in multiple malignancies. Transcriptomic deconvolution revealed a clear positive correlation between GAS6 levels and macrophage infiltration and polarization. Our study systematically revealed the evidence establishing GAS6 as an oncogenic driver and a regulator of the immunosuppressive microenvironment across human cancers. These findings furnish a mechanistic rationale for therapeutically targeting the GAS6/TAM axis to subvert immune tolerance and potentiate chemoradiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.